{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:17Z","timestamp":1707524297247},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,13]]},"DOI":"10.7759\/cureus.15014","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:34:04Z","timestamp":1620938044000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-Uremic Calciphylaxis: An Unexpected Complication With Recombinant Human Parathyroid Hormone"],"prefix":"10.7759","author":[{"given":"Cory","family":"DeClue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Chinnakotla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505292","article-title":"Calciphylaxis","volume":"378","author":"Nigwekar SU","year":"2018","unstructured":"Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018, 378:1704-1714. 10.1056\/NEJMra1505292","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv438","article-title":"Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry","volume":"32","author":"Brandenburg VM","year":"2017","unstructured":"Brandenburg VM, Kramann R, Rothe H, et al.. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant. 2017, 32:126-132. 10.1093\/ndt\/gfv438","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.06.001","article-title":"Calciphylaxis in patients with normal renal function: a case series and systematic review","volume":"93","author":"Bajaj R","year":"2018","unstructured":"Bajaj R, Courbebaisse M, Kroshinsky D, Thadhani RI, Nigwekar SU. Calciphylaxis in patients with normal renal function: a case series and systematic review. Mayo Clin Proc. 2018, 93:1202-1212. 10.1016\/j.mayocp.2018.06.001","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00530108","article-title":"Calciphylaxis from nonuremic causes: a systematic review","volume":"3","author":"Nigwekar SU","year":"2008","unstructured":"Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008, 3:1139-1143. 10.2215\/CJN.00530108","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2012.01.023","article-title":"Cutaneous vascular calcifications secondary to treatment with teriparatide","volume":"104","author":"Leis-Dosil VM","year":"2013","unstructured":"Leis-Dosil VM, Rubio Flores C, Ruiz-Bravo E, Diaz-Diaz RM. Cutaneous vascular calcifications secondary to treatment with teriparatide. Acta Dermosifiliogr. 2013, 104:87-88. 10.1016\/j.ad.2012.01.023","journal-title":"Acta Dermosifiliogr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.013","article-title":"Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide","volume":"70","author":"Dominguez AR","year":"2014","unstructured":"Dominguez AR, Goldman BA. Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide. J Am Acad Dermatol. 2014, 70:41-42. 10.1016\/j.jaad.2013.10.013","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3571-1","article-title":"Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment","volume":"27","author":"Monegal A","year":"2016","unstructured":"Monegal A, Peris P, Alsina M, Colmenero J, Guanabens N. Development of multiorganic calciphylaxis during teriparatide, vitamin D, and calcium treatment. Osteopor Int. 2016, 27:2631-2634. 10.1007\/s00198-016-3571-1","journal-title":"Osteopor Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2580-6","article-title":"Nonuremic calciphylaxis precipitated by teriparatide [rhPTH (1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment","volume":"25","author":"Spanakis EK","year":"2014","unstructured":"Spanakis EK, Sellmeyer DE. Nonuremic calciphylaxis precipitated by teriparatide [rhPTH (1-34)] therapy in the setting of chronic warfarin and glucocorticoid treatment. Osteopor Int. 2014, 25:1411-1414. 10.1007\/s00198-013-2580-6","journal-title":"Osteopor Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016060651","article-title":"Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis","volume":"28","author":"Nigwekar SU","year":"2017","unstructured":"Nigwekar SU, Bloch DB, Nazarian RM, et al.. Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis. J Am Soc Nephrol. 2017, 28:1717-1722. 10.1681\/ASN.2016060651","journal-title":"J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12021","article-title":"Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure","volume":"18","author":"Smith ER","year":"2013","unstructured":"Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG. Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology (Carlton). 2013, 18:215-221. 10.1111\/nep.12021","journal-title":"Nephrology (Carlton)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.05.005","article-title":"Adipocyte induced arterial calcification is prevented with sodium thiosulfate","volume":"449","author":"Chen NX","year":"2014","unstructured":"Chen NX, O'Neill K, Akl NK, Moe SM. Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochem Biophys Res Commun. 2014, 449:151-156. 10.1016\/j.bbrc.2014.05.005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan CM","year":"2011","unstructured":"Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM, Towler DA. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011, 109:697-711. 10.1161\/CIRCRESAHA.110.234914","journal-title":"Circ Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2015.07.045","article-title":"Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: a possible role for IL\u20101\u03b2","volume":"589","author":"Bessueille L","year":"2015","unstructured":"Bessueille L, Fakhry M, Hamade E, Badran B, Magne D. Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: a possible role for IL\u20101\u03b2. FEBS Lett. 2015, 589:2797-2804. 10.1016\/j.febslet.2015.07.045","journal-title":"FEBS Lett"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASW.0000554443.14002.13","article-title":"Calciphylaxis: diagnosis, pathogenesis, and treatment","volume":"32","author":"Chang JJ","year":"2019","unstructured":"Chang JJ. Calciphylaxis: diagnosis, pathogenesis, and treatment. Adv Skin Wound Care. 2019, 32:205-215. 10.1097\/01.ASW.0000554443.14002.13","journal-title":"Adv Skin Wound Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000491881","article-title":"The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis","volume":"48","author":"Garza-Mayers AC","year":"2018","unstructured":"Garza-Mayers AC, Shah R, Sykes DB, Nigwekar SU, Kroshinsky D. The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis. Am J Nephrol. 2018, 48:168-171. 10.1159\/000491881","journal-title":"Am J Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5414\/CN107923","article-title":"Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates","volume":"83","author":"Torregrosa JV","year":"2015","unstructured":"Torregrosa JV, Sanchez-Escuredo A, Barros X, Blasco M, Campistol JM. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clin Nephrol. 2015, 83:231-234. 10.5414\/CN107923","journal-title":"Clin Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13081","article-title":"Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients","volume":"23","author":"Peng T","year":"2018","unstructured":"Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, Hong D. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton). 2018, 23:669-675. 10.1111\/nep.13081","journal-title":"Nephrology (Carlton)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx126","article-title":"Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation","volume":"11","author":"Christiadi D","year":"2018","unstructured":"Christiadi D, Singer RF. Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation. Clin Kidney J. 2018, 11:528-529. 10.1093\/ckj\/sfx126","journal-title":"Clin Kidney J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00631-0","article-title":"Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis","volume":"32","author":"Brandenburg VM","year":"2019","unstructured":"Brandenburg VM, Sinha S, Torregrosa JV, et al.. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J Nephrol. 2019, 32:811-821. 10.1007\/s40620-019-00631-0","journal-title":"J Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/44743-non-uremic-calciphylaxis-an-unexpected-complication-with-recombinant-human-parathyroid-hormone","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:19Z","timestamp":1707506899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/44743-non-uremic-calciphylaxis-an-unexpected-complication-with-recombinant-human-parathyroid-hormone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.15014","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,13]]}}}